Skip to main content
. 2021 May 12;8:643127. doi: 10.3389/fcvm.2021.643127

Figure 3.

Figure 3

Cumulative incidence curve for follow-up mortality classified according to the fibrosis (A), MELD (B), and ALBI score (C). MELD, model of end-stage liver disease; ALBI, albumin–bilirubin; MACE, major adverse clinical events.